The relatively small number of claims for adverse events attributed to corticosteroids cited in the 10-year survey from Boston, Mass,1 may require amplification. Among the nearly 40 cases I have reviewed (either on behalf of defendants or plaintiffs) as an "expert witness" over the past 30 plus years,2 there were 21 malpractice claims for irreversible bone destruction, or avascular necrosis, following the administration of high doses of oral or parenteral corticosteroids for variable periods of time. Two of these were from the Boston area and may not have been included in the published survey that ended in 1999. Practically all the cases brought to my attention by legal counsels in several locations (only 1 from my own state of Colorado) could be considered what the authors label "preventable." Dosages exceeded 40 to 60 mg of prednisone, or the equivalent, per day—in some instances 250 to 500 mg of intravenous methylprednisolone—for conditions that were neither life-threatening nor potentially disabling. Lack of prompt improvement for mostly respiratory asthmalike illnesses and for 1 case of contact dermatitis led to ever increasing corticosteroid use when the underlying problem and the therapeutic unresponsiveness turned out to be due to an infection. In most cases the settlements and other expenditures were much above the costs reported from Massachusetts but still seemed inadequate to compensate for the iatrogenic disability and suffering of these relatively young patients.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature Consider an RCT of corticosteroids in patients with an acute exacerbation of chronic obstructive...
The Rational Clinical Examination Evidence Summary and Review 5
All results at JAMAevidence.com >
and access these and other features:
Register Now
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Need assistance?
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.